Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629376 | 0.84 | TP53 (0.50) | THRBLMNAGAAL3MBTL1RXFP1 | |
| SCHEMBL6050631 | 0.84 | THRB (0.46) | THRBLMNAGAAL3MBTL1NTRK1 | |
| SCHEMBL11400290 | 0.84 | THRB (0.46) | THRBLMNAGAAL3MBTL1NTRK1 | |
| SCHEMBL7204371 | 0.83 | ATM (0.44) | THRBLMNAL3MBTL1POLBTP53 | |
| SCHEMBL10631654 | 0.83 | THRB (0.45) | THRBLMNAGAAL3MBTL1NTRK1 | |
| SCHEMBL10629380 | 0.81 | THRB (0.43) | THRBLMNAGAAL3MBTL1NTRK1 | |
| SCHEMBL10631490 | 0.80 | POLB (0.49) | LMNAGAAPOLBTP53 | |
| SCHEMBL10627413 | 0.80 | SCN9A (0.42) | TP53MAT2A | |
| SCHEMBL10631570 | 0.80 | GPR84 (0.49) | LMNAL3MBTL1POLBCA2 | |
| SCHEMBL10627386 | 0.78 | TP53 (0.47) | THRBLMNARXFP1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4772614-A | QUINOLINOLS | THE BOOTS COMPANY (GB) | 1988-09-20 | — | — | US | claimed |
| EP-0206616-A2 | Quinolones having antihypertensive activity | The Boots Company PLC (GB) | 1986-12-30 | — | — | EP | claimed |
| US-6995173-B2 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1355647-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. Alamo Ventures I, LLC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC | 2003-07-10 | — | — | US | disclosed |
| US-6562838-B2 | Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced | R. T. ALAMO VENTURES I, L.L.C. | 2003-05-13 | — | — | US | disclosed |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| WO-2002058703-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. ALAMO VENTURES I, LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| US-4772614-A | QUINOLINOLS | THE BOOTS COMPANY (GB) | 1988-09-20 | — | — | US | disclosed |
| EP-0206616-A2 | Quinolones having antihypertensive activity | The Boots Company PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | THRB 3646/4885LMNA 1679/4885GAA 566/4885 |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | PMP22, NLN, SLC6A2 | THRB 1895/4885LMNA 3541/4885GAA 332/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | THRB 3646/4885LMNA 1679/4885GAA 566/4885 |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | PMP22, NLN, SLC6A2 | THRB 1895/4885LMNA 3541/4885GAA 332/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | THRB 2505/4885LMNA 3063/4885GAA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.